U.S. License Holder:
Ultragenyx Pharmaceutical Inc.
Date of License:
November-15-2017
Last Update:
Dec-15-2024
FDA-Approved Indications
MEPSEVII (vestronidase alfa-vjbk) is a recombinant human lysosomal beta glucuronidase indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).